Jack Szaniawski napisał:

> Jacek <p...@p...onet.pl> wrote:
>
> >wydaje mi sie ze opalanie jest jednak zdrowe, umozliwia synteze witaminy D i
> >pewnie 1000 innych
> >substancji.
> .......itd w podobnym stylu
>
> ja pisze co wynika z badan a nie co sie wydaje. jakby wazniejsze bylo
> to, co sie laikom wydaje nie wydawanoby np. setek milionow dolarow na
> badanie dalania lekow.
>
> przepraszam, ale nie bede juz odpowiadac. za duza roznica poziomow
> wiedzy

aby wzbogacic te wiedze, kilka slow nt. Merck'a, 2-go wedlug wielkosci
amerykanskiego producenta lekow

z Bloomberga
Merck shares fell 30 cents to $67 in late morning trading. The shares have
dropped 28 percent this year because of concerns about
Vioxx. Merck last
month lowered its estimate of 2001 Vioxx sales from an
earlier high of $3.5
billion.

Vioxx Sales Force

Merck has hired 1,000 sales representatives this year,
giving it more people to
visit doctors and promote Vioxx, said Laura Jordan of
Merck's investor relations
department.

``All of those people are now out (promoting) Vioxx,'' she
said on a conference
call.

Merck needs to raise sales of Vioxx as generic competition
reduces sales of
other medicines. Sales of the Vasotec high-blood- pressure
drug fell 44 percent
to $295 million, with an 80 percent decline in U.S. sales.
Sales of the Pepcid
ulcer drug fell 49 percent to $110 million, with a 54
percent decline in U.S. sales.

Along with Vioxx, sales of other newer Merck drugs rose.
Sales of the Singulair
asthma drug rose 79 percent to $375 million. Sales of
Fosamax rose 51 percent
to $490 million. Sales of Merck's biggest drug, the Zocor
cholesterol reducer,
rose 5 percent to $1.36 billion.